BUZZ-Myriad Genetics Inc: Cuts revenue, profit forecast for full year

Tue Feb 3, 2015 5:38pm EST
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Molecular diagnostic's shares down 16 pct at $31.78 in extended trading

** Company cuts revenue forecast to $730 mln-$740 mln for year ending June 30 from $800-$820 mln; adjusted profit/shr forecast to $1.50-$1.55 from $1.75-$1.85

** Says cut due to lag in getting reimbursement coverage for diagnostic services and increase in work-in-process

** CEO Peter Meldrum leaves company; To be suceeded by Mark Capone

** Stock gained 62 pct in 2014